{"_buckets": {"deposit": "a6b3cb98-0308-47ca-881c-782649db6221"}, "_deposit": {"id": "14960", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "14960"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00014960", "sets": ["456", "1076"]}, "item_7_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Characteristics and Treatment of Steroid Induced Osteoporosis"}]}, "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2001-04", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "4", "bibliographicPageEnd": "131", "bibliographicPageStart": "126", "bibliographicVolumeNumber": "115", "bibliographic_titles": [{"bibliographic_title": "新潟医学会雑誌"}, {"bibliographic_title": "新潟医学会雑誌", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Due to the development of immunological examinations, early diagnosis and treatment of collagen vascular diseases such as systemic lupus erythematosis (SLE) has been made possible and the prognosis for these diseases has improved. However, steroid induced osteoporosis followed by compression fracture of spinal bone has become a serious complication for long term therapy. Steroids are known to increase urinary calcium excretion. Alfacalcidol, used for oteoporosis, also increases urinary calcium excretion and induces renal stone formation. Two newly developed drugs approved by the Health and Welfare Ministry, etidronate and menatetrenone, were recently shown to decrease urinary calcium excretion. We are currently studying the effect of alfacalcidol and etidronate on steroid induced osteoporosis. With 9 subjects in each of two groups, we are measuring markers of bone turnover (serum osteocalcin and urinary deoxypyridinoline), urinary calcium excretion and bone mineral content measured by DEXA. To date, no remarkable differences have been observed. Larger patient groups for this prospective study are necessary, and will be enrolled, to clarify the efficacy of etidronate for steroid induced osteoporosis.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "96350", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Ito, Satoshi"}]}]}, "item_7_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "新潟医学会"}]}, "item_7_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "伊藤, 聡"}], "nameIdentifiers": [{"nameIdentifier": "96349", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-07"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "115(4)_126-131.pdf", "filesize": [{"value": "1.3 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1300000.0, "url": {"label": "115(4)_126-131.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/14960/files/115(4)_126-131.pdf"}, "version_id": "50131720-e78e-4881-9705-5b9440ce2df3"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "steroid hormon", "subitem_subject_scheme": "Other"}, {"subitem_subject": "osteoporosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "renal stone", "subitem_subject_scheme": "Other"}, {"subitem_subject": "alfacalcidol", "subitem_subject_scheme": "Other"}, {"subitem_subject": "etidronate", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ステロイドホルモン", "subitem_subject_scheme": "Other"}, {"subitem_subject": "骨粗鬆症", "subitem_subject_scheme": "Other"}, {"subitem_subject": "腎結石", "subitem_subject_scheme": "Other"}, {"subitem_subject": "アルファカルシドール", "subitem_subject_scheme": "Other"}, {"subitem_subject": "エチドロネート", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "4) ステロイド誘発性骨粗鬆症の病態と治療（シンポジウム 骨粗鬆症の病態と治療, 第554回新潟医学会）", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "4) ステロイド誘発性骨粗鬆症の病態と治療（シンポジウム 骨粗鬆症の病態と治療, 第554回新潟医学会）"}, {"subitem_title": "4) ステロイド誘発性骨粗鬆症の病態と治療（シンポジウム 骨粗鬆症の病態と治療, 第554回新潟医学会）", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["456", "1076"], "permalink_uri": "http://hdl.handle.net/10191/48115", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-11-07"}, "publish_date": "2017-11-07", "publish_status": "0", "recid": "14960", "relation": {}, "relation_version_is_last": true, "title": ["4) ステロイド誘発性骨粗鬆症の病態と治療（シンポジウム 骨粗鬆症の病態と治療, 第554回新潟医学会）"], "weko_shared_id": null}